Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study

Banegas, José R., López-García, Esther, Dallongeville, Jean, Guallar, Eliseo, Halcox, Julian P. J., Borghi, Claudio, Massó-González, Elvira L., Sazova, Ogün, Perk, Joep, Steg, Philippe Gabriel, De Backer, Guy and Rodríguez-Artalejo, Fernando 2011. Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. International Journal of Cardiology 166 (1) , pp. 210-214. 10.1016/j.ijcard.2011.10.094

Full text not available from this repository.

Abstract

Objective To examine for the first time the achievement of lipoprotein treatment goals in patients with metabolic syndrome and lipid abnormalities who are at elevated cardiovascular risk in Europe. Methods Cross-sectional study conducted in 2009–2010 in 12 European countries among outpatients aged ≥ 50 years free of clinical cardiovascular disease. We assessed achievement of American Diabetes Association/American College of Cardiology lipid treatment goals in those with metabolic syndrome at highest risk (diabetes plus ≥ 1 additional major cardiovascular risk factor beyond lipid abnormalities) or high risk (no diabetes but ≥ 2 additional major cardiovascular risk factors). Results Among 1431 highest-risk patients, 64.6% (between-country range [BCR] 40–84.5%) were on lipid-lowering medication. Of them, 13.4% (BCR: 2.5–28.6%) had LDL-cholesterol < 70 mg/dl, non-HDL-cholesterol < 100 mg/dl, and apolipoprotein B < 80 mg/dl. Among 832 high-risk patients, 38.7% BCR: 27.5–55.3%) were on lipid-lowering medication. Of them, 20.5% (BCR: 5.5–57.6%) had LDL-cholesterol < 100 mg/dl, non-HDL-cholesterol < 130 mg/dl, and apolipoprotein B < 90 mg/dl. About 96% of highest-risk patients and 94% of high-risk patients were given at least one lifestyle advice (weight reduction, healthy diet, physical activity, no-smoking), but only 1.3% of the former and 4.9% of the latter reached all three lipid goals. Conclusion There is a substantial gap between clinical guidelines and medical practice since only one in 5–7 patients met all treatment targets. Although most patients received lifestyle advice, the effectiveness of counseling was very low. Large between-country differences in outcomes suggest considerable room for improvement.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	cardiometabolic syndrome, primary prevention, goal, dyslipidemia, diabetes, europe
Publisher:	Elsevier
ISSN:	0167-5273
Last Modified:	19 Mar 2016 22:43
URI:	https://orca.cardiff.ac.uk/id/eprint/25295

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item